Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19436556 | 1.00 | STING1 (0.76) | STING1TBK1 | |
| Hydrochloric Acid SCHEMBL23228019 | 0.99 | STING1 (0.75) | STING1TBK1 | |
| Hydrochloric Acid SCHEMBL23228017 | 0.99 | STING1 (0.75) | STING1TBK1 | |
| SCHEMBL29702138 | 0.96 | STING1 (0.81) | STING1TBK1 | |
| SCHEMBL19451632 | 0.96 | STING1 (0.81) | STING1TBK1 | |
| SCHEMBL19451795 | 0.93 | STING1 (0.76) | STING1TBK1 | |
| SCHEMBL23227750 | 0.93 | STING1 (0.76) | STING1TBK1 | |
| SCHEMBL19451598 | 0.93 | STING1 (0.76) | STING1TBK1 | |
| SCHEMBL29702127 | 0.93 | STING1 (0.76) | STING1TBK1 | |
| Hydrochloric Acid SCHEMBL22121574 | 0.92 | STING1 (0.66) | STING1TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11970480-B2 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-04-30 | — | — | US | disclosed |
| WO-2023215740-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | SEAGEN INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230071675-A1 | Heterocyclic Amides Useful as Protein Modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-03-09 | — | — | US | disclosed |
| US-11365190-B2 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-06-21 | — | — | US | disclosed |
| EP-3440076-B1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-06-01 | — | — | EP | disclosed |
| US-11155567-B2 | Sting agonist compounds and methods of use | MERSANA THERAPEUTICS, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| CN-110016025-B | Immunomodulator | 成都先导药物开发股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-20210238172-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS AND METHODS OF USING THE SAME | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-05 | — | — | US | disclosed |
| US-20210238172-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS AND METHODS OF USING THE SAME | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-05 | — | — | US | disclosed |
| US-20210139473-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| US-20210032269-A1 | STING AGONIST COMPOUNDS AND METHODS OF USE | MERSANA THERAPEUTICS, INC. | 2021-02-04 | — | — | US | disclosed |
| EP-3692033-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) USEFUL IN TREATING HIV | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-08-12 | — | — | EP | disclosed |
| WO-2020132582-A1 | STING AGONISTS AND USES THEREOF | NIMBUS TITAN, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2019069269-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) USEFUL IN TREATING HIV | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-11 | — | — | WO | disclosed |
| EP-3440076-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2019-02-13 | — | — | EP | disclosed |
| US-10189820-B2 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-29 | — | — | US | disclosed |
| US-20180105514-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-19 | — | — | US | disclosed |
| US-20180105514-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-19 | — | — | US | disclosed |
| WO-2017175147-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017175147-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189820-B2 | Heterocyclic amides useful as protein modulators | RB1, RBBP5, RCC2 | STING1 3127/4885TBK1 2185/4885 |
| US-11970480-B2 | Heterocyclic amides useful as protein modulators | RB1, RBBP5, RCC2 | STING1 3127/4885TBK1 2185/4885 |
| US-11365190-B2 | Heterocyclic amides useful as protein modulators | RB1, RBBP5, RCC2 | STING1 3127/4885TBK1 2185/4885 |
| US-11155567-B2 | Sting agonist compounds and methods of use | STING1, IRF3, MAVS | STING1 1/4885TBK1 6/4885 |
| US-20210238172-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS AND METHODS OF USING THE SAME | AADAC, TAF15, HDAC10 | STING1 748/4885TBK1 1160/4885 |
| US-20210139473-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | RB1, RBBP5, RCC2 | STING1 3127/4885TBK1 2185/4885 |
| US-20180105514-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | RB1, RBBP5, RCC2 | STING1 3127/4885TBK1 2185/4885 |
| US-20230071675-A1 | Heterocyclic Amides Useful as Protein Modulators | RB1, RBBP5, RCC2 | STING1 3127/4885TBK1 2185/4885 |
| US-20210032269-A1 | STING AGONIST COMPOUNDS AND METHODS OF USE | STING1, IRF3, MAVS | STING1 1/4885TBK1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.